Publications
205
Citations
43,053
Est. group size
—
Recurring co-author estimate
Active years
29
Publishing since 1998
- Predictors of real-world progression-free survival (rwPFS) in patients (pts) with epithelial ovarian cancer (EOC) treated with first-line maintenance (1LM) niraparib (nir): Post hoc analysis of the 1NSPIRE chart review study.
Journal of Clinical Oncology · 2026
- A phase 2, open-label, multi-center, single-arm study of atezolizumab and bevacizumab in the treatment of second line and beyond, recurrent/metastatic endometrial cancer.
Journal of Clinical Oncology · 2026
- Vaginal Cancer, Version 2.2026, NCCN Clinical Practice Guidelines In Oncology
Journal of the National Comprehensive Cancer Network · 2026
- Updated overall survival analysis and examination of subsequent therapy in endometrial cancer (EC) patients (pts) treated with pembrolizumab plus carboplatin/paclitaxel (CP) as compared to CP plus placebo (PBO) in the NRG-GY018 trial.
Journal of Clinical Oncology · 2026
- Feasibility IB trial of paclitaxel/carboplatin + Galunisertib. (a small molecule inhibitor of the kinase domain of type 1 TGF-B receptor) in patients with newly diagnosed, persistent or recurrent carcinosarcoma of the uterus or ovary
Gynecologic Oncology · 2025
- PEMBROLIZUMAB PLUS ADJUVANT CHEMOTHERAPY WITH OR WITHOUT RADIOTHERAPY FOR NEWLY DIAGNOSED HIGH-RISK ENDOMETRIAL CANCER: HEALTH-RELATED QUALITY OF LIFE (HRQOL) FROM THE PHASE 3 ENGOT-EN11/GOG-3053/KEYNOTE-B21 STUDY
International Journal of Gynecological Cancer · 2025
- SURVIVAL AND SAFETY OUTCOMES IN PART 1 OF THE ENGOT-EN6-NSGO/GOG-3031/RUBY TRIAL OF DOSTARLIMAB PLUS CARBOPLATIN-PACLITAXEL IN THE PRESENCE OF COMMON COMORBIDITIES
International Journal of Gynecological Cancer · 2025
- 1227eP Real-world (rw) outcomes in patients (pts) with epithelial ovarian cancer (EOC) who received first-line maintenance (1LM) niraparib: Final results from the 1NSPIRE chart review study
Annals of Oncology · 2025
- A plain language summary publication of patients’ survival with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel
Therapeutic Advances in Medical Oncology · 2025
- Predictive biomarkers for chemotherapy plus bevacizumab in recurrent/metastatic cervical cancer: The NRG Oncology/GOG-0240 National Institutes of Health Cancer Moonshot
Gynecologic Oncology · 2025
- Real-world clinical management of decreased platelet counts in patients with epithelial ovarian cancer who received first-line maintenance niraparib in the ACTIV1ZE study
Gynecologic Oncology · 2025
- Real-world outcomes in patients with epithelial ovarian cancer who received first-line maintenance niraparib: Interim results from the 1NSPIRE chart review study
Gynecologic Oncology · 2025
- Frontline immunotherapy combined with radiation and chemotherapy in high-risk endometrial cancer (FIERCE)
Gynecologic Oncology · 2025
- Post hoc tipping point and multiple imputation analyses to determine the impact of early censored patients in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial
Gynecologic Oncology · 2025
- Machine learning approach for risk-based prediction of endometrial cancer recurrence
Gynecologic Oncology · 2025
- Gynecologic Oncology×28
- International Journal of Gynecological Cancer×11
- Journal of Clinical Oncology×10
- Annals of Oncology×4
- Elsevier eBooks×4
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 9, 2026.
Claim or correct this profile